Terms: = Lung cancer AND KMT2D, ENSG00000167548, 8085, MLL2
128 results:
1. Molecular Pathogenesis, Organ Metastasis, and Targeted Therapy for Non-Small-Cell lung cancer.
Abdullah S; Chakraborty R; Kumkar PS; Debnath B; Bala A
J Environ Pathol Toxicol Oncol; 2024; 43(3):13-38. PubMed ID: 38608143
[TBL] [Abstract] [Full Text] [Related]
2. CRISPR/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam/Cabs1 gene cluster expression.
Cai H; Zhang B; Ahrenfeldt J; Joseph JV; Riedel M; Gao Z; Thomsen SK; Christensen DS; Bak RO; Hager H; Vendelbo MH; Gao X; Birkbak N; Thomsen MK
Nat Commun; 2024 Mar; 15(1):2088. PubMed ID: 38453924
[TBL] [Abstract] [Full Text] [Related]
3. Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non-small cell lung cancer.
Xin Y; Liu CG; Zang D; Chen J
Front Immunol; 2024; 15():1343450. PubMed ID: 38361936
[TBL] [Abstract] [Full Text] [Related]
4. Investigation of Mirna-223-3p Expression in Non-small Cell lung cancers.
Barut Z; Akdeniz FT; Isbir T
Anticancer Res; 2024 Feb; 44(2):585-591. PubMed ID: 38307576
[TBL] [Abstract] [Full Text] [Related]
5. Identification of Candidate mRNA Genes and Their Potential MicroRNA Targets in lung cancer Induced by Smoking Tobacco.
Mishra AK; Mumtaz N; Misra MK
Front Biosci (Schol Ed); 2023 Nov; 15(4):13. PubMed ID: 38163953
[TBL] [Abstract] [Full Text] [Related]
6. A cisplatin and disulphiram co-loaded inclusion complex overcomes drug resistance by inhibiting cancer cell stemness in non-small cell lung cancer.
Ye W; Lv H; Zhang Q; Zhao J; Zhao X; Zhao G; Yan C; Sun F; Zhao Z; Jia X
J Drug Target; 2024 Dec; 32(2):159-171. PubMed ID: 38133515
[No Abstract] [Full Text] [Related]
7. Z-Ligustilide Combined with Cisplatin Reduces PLPP1-Mediated Phospholipid Synthesis to Impair Cisplatin Resistance in lung cancer.
Geng P; Zhao J; Li Q; Wang X; Qin W; Wang T; Shi X; Liu X; Chen J; Qiu H; Xu G
Int J Mol Sci; 2023 Dec; 24(23):. PubMed ID: 38069368
[TBL] [Abstract] [Full Text] [Related]
8. Identifying survival of pan-cancer patients under immunotherapy using genomic mutation signature with large sample cohorts.
Zhang L; Wang Y; Wang L; Wang M; Li S; He J; Ji J; Li K; Cao L
J Mol Med (Berl); 2024 Jan; 102(1):69-79. PubMed ID: 37978056
[TBL] [Abstract] [Full Text] [Related]
9. DNA damage response and repair gene mutations are associated with tumor mutational burden and outcomes to platinum-based chemotherapy/immunotherapy in advanced NSCLC patients.
Gu W; Zhuang W; Zhuang M; He M; Li Z
Diagn Pathol; 2023 Nov; 18(1):119. PubMed ID: 37924135
[TBL] [Abstract] [Full Text] [Related]
10. Exploring the molecular features and genetic prognostic factors of pulmonary high-grade neuroendocrine carcinomas.
Wang H; Yan L; Zhu Y; Sun W; Yang X; Liu X; Chi K; Huang X; Zhou L; Lin D
Hum Pathol; 2023 Dec; 142():81-89. PubMed ID: 37742943
[TBL] [Abstract] [Full Text] [Related]
11. Meta-analysis of commonly mutated genes in leptomeningeal carcinomatosis.
Congur I; Koni E; Onat OE; Tokcaer Keskin Z
PeerJ; 2023; 11():e15250. PubMed ID: 37096065
[TBL] [Abstract] [Full Text] [Related]
12. Heat Shock Proteins in Non-Small-Cell lung cancer-Functional Mechanism.
Zhou G; Pu Y; Zhao K; Chen Y; Zhang G
Front Biosci (Landmark Ed); 2023 Mar; 28(3):56. PubMed ID: 37005758
[TBL] [Abstract] [Full Text] [Related]
13. MLL4 Regulates the Progression of Non-Small-Cell lung cancer by Regulating the PI3K/AKT/SOX2 Axis.
Yang Y; Qiu R; Weng Q; Xu Z; Song J; Zhao S; Meng M; Zhang D; Kong C; Wang H; Xu M; Zhao Z; Ji J
Cancer Res Treat; 2023 Jul; 55(3):778-803. PubMed ID: 36701842
[TBL] [Abstract] [Full Text] [Related]
14. Immunotherapeutics in lung cancers: from mechanistic insight to clinical implications and synergistic perspectives.
Tuli HS; Garg VK; Choudhary R; Iqubal A; Sak K; Saini AK; Saini RV; Vashishth K; Dhama K; Mohapatra RK; Gupta DS; Kaur G
Mol Biol Rep; 2023 Mar; 50(3):2685-2700. PubMed ID: 36534236
[TBL] [Abstract] [Full Text] [Related]
15. kmt2d deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition.
Pan Y; Han H; Hu H; Wang H; Song Y; Hao Y; Tong X; Patel AS; Misirlioglu S; Tang S; Huang HY; Geng K; Chen T; Karatza A; Sherman F; Labbe KE; Yang F; Chafitz A; Peng C; Guo C; Moreira AL; Velcheti V; Lau SCM; Sui P; Chen H; Diehl JA; Rustgi AK; Bass AJ; Poirier JT; Zhang X; Ji H; Zhang H; Wong KK
Cancer Cell; 2023 Jan; 41(1):88-105.e8. PubMed ID: 36525973
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic impact of tumour mutational burden in resected stage I and II lung adenocarcinomas from a European Thoracic Oncology Platform lungscape cohort.
Bubendorf L; Zoche M; Dafni U; Rüschoff JH; Prince SS; Marti N; Stavrou A; Kammler R; Finn SP; Moch H; Peters S; Stahel RA
Lung Cancer; 2022 Dec; 174():27-35. PubMed ID: 36283211
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic biomarkers correlated with immune infiltration in non-small cell lung cancer.
Xu F; Cui WQ; Liu C; Feng F; Liu R; Zhang J; Sun CG
FEBS Open Bio; 2023 Jan; 13(1):72-88. PubMed ID: 36282125
[TBL] [Abstract] [Full Text] [Related]
18. Interaction of MRPL9 and GGCT Promotes Cell Proliferation and Migration by Activating the MAPK/ERK Pathway in Papillary Thyroid cancer.
Zhang HM; Li ZY; Dai ZT; Wang J; Li LW; Zong QB; Li JP; Zhang TC; Liao XH
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233293
[TBL] [Abstract] [Full Text] [Related]
19. Construction and evaluation of a prognostic risk model of tumor metastasis-related genes in patients with non-small cell lung cancer.
Ding H; Shi L; Chen Z; Lu Y; Tian Z; Xiao H; Deng X; Chen P; Zhang Y
BMC Med Genomics; 2022 Sep; 15(1):187. PubMed ID: 36056349
[TBL] [Abstract] [Full Text] [Related]
20. Mutational landscape of homologous recombination-related genes in small-cell lung cancer.
Wu S; Zhang Y; Zhang Y; Chen LH; Ouyang HF; Xu X; Du Y; Ti XY
Cancer Med; 2023 Feb; 12(4):4486-4495. PubMed ID: 36053931
[TBL] [Abstract] [Full Text] [Related]
[Next]
